Majority of UK NICE decisions 'still centered on cost-effectiveness'
This article was originally published in SRA
A new analysis has found that despite NICE claims that cost-effectiveness is not the only consideration in its health technology assessments (HTAs), cost-effectiveness alone correctly predicted 82% of the decisions made by the HTA body for England and Wales through the end of 2011.
You may also be interested in...
Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.
Schemes and funding to support growth in the life sciences and medtech sectors featured in the UK government’s spring budget on 3 March.